Bleomycin induces endothelial mesenchymal transition through activation of mTOR pathway: A possible mechanism contributing to the sclerotherapy of venous malformations

British Journal of Pharmacology

Volumn 170, Issue 6, 2013, Pages 1210-1220

  Zhang, Wei ^a   Chen, Gang ^a   Ren, Jian Gang ^a   Zhao, Yi Fang ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

bleomycin; endothelial mesenchymal transition; mTOR; Slug; venous malformation

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BLEOMYCIN; CADHERIN; CALVASCULIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; TRANSCRIPTION FACTOR SLUG;

ARTICLE; CELL FUNCTION; CELL MIGRATION; CELL SIZE; CELL TRANSFORMATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIAL MESENCHYMAL TRANSITION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BLEOMYCIN; ENDOTHELIAL MESENCHYMAL TRANSITION; MTOR; SLUG; VENOUS MALFORMATION;

BLEOMYCIN; CELL MOVEMENT; CELL TRANSDIFFERENTIATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; PROTO-ONCOGENE PROTEINS C-AKT; SCLEROSING SOLUTIONS; SCLEROTHERAPY; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; VASCULAR DISEASES; VEINS;

EID: 84886783076     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12355     Document Type: Article

References (39)

1. Arciniegas E, Neves CY, Carrillo LM, Zambrano EA, Ramirez R, (2005). Endothelial-mesenchymal transition occurs during embryonic pulmonary artery development. Endothelium 12: 193-200.
2. Dompmartin A, Vikkula M, Boon LM, (2010). Venous malformation: update on aetiopathogenesis, diagnosis and management. Phlebology 25: 224-235.
3. Feng S, Cen J, Huang Y, Shen H, Yao L, Wang Y, et al. (2011). Matrix metalloproteinase-2 and -9 secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight junction proteins. PLoS ONE 6: e20599.
4. Goc A, Choudhary M, Byzova TV, Somanath PR, (2011). TGFbeta- and bleomycin-induced extracellular matrix synthesis is mediated through Akt and mammalian target of rapamycin (mTOR). J Cell Physiol 226: 3004-3013.
5. Harrison JH, Jr, Lazo JS, (1987). High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis. J Pharmacol Exp Ther 243: 1185-1194.
6. Hashimoto N, Phan SH, Imaizumi K, Matsuo M, Nakashima H, Kawabe T, et al. (2010). Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 43: 161-172.
7. Horikawa M, Fujimoto M, Hasegawa M, Matsushita T, Hamaguchi Y, Kawasuji A, et al. (2006). E- and P-selectins synergistically inhibit bleomycin-induced pulmonary fibrosis. Am J Pathol 169: 740-749.
8. Hwang ES, Yoon G, Kang HT, (2009). A comparative analysis of the cell biology of senescence and aging. Cell Mol Life Sci 66: 2503-2524.
9. Jia J, Zhang W, Liu JY, Chen G, Liu H, Zhong HY, et al. (2012). Epithelial mesenchymal transition is required for acquisition of anoikis resistance and metastatic potential in adenoid cystic carcinoma. PLoS ONE 7: e51549.
10. Jiang CG, Lv L, Liu FR, Wang ZN, Na D, Li F, et al. (2013). Connective tissue growth factor is a positive regulator of epithelial-mesenchymal transition and promotes the adhesion with gastric cancer cells in human peritoneal mesothelial cells. Cytokine 61: 173-180.
11. Koitabashi N, Danner T, Zaiman AL, Pinto YM, Rowell J, Mankowski J, et al. (2011). Pivotal role of cardiomyocyte TGF-beta signaling in the murine pathological response to sustained pressure overload. J Clin Invest 121: 2301-2312.
12. Korfhagen TR, Le Cras TD, Davidson CR, Schmidt SM, Ikegami M, Whitsett JA, et al. (2009). Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 41: 562-572.
13. Lamouille S, Derynck R, (2007). Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 178: 437-451.
14. Lamouille S, Connolly E, Smyth JW, Akhurst RJ, Derynck R, (2012). TGF-beta-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci 125 (Pt 5): 1259-1273.
15. Laplante P, Sirois I, Raymond MA, Kokta V, Beliveau A, Prat A, et al. (2010). Caspase-3-mediated secretion of connective tissue growth factor by apoptotic endothelial cells promotes fibrosis. Cell Death Differ 17: 291-303.
16. Lau MT, Leung PC, (2012). The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells. Cancer Lett 326: 191-198.
17. Li J, Qu X, Yao J, Caruana G, Ricardo SD, Yamamoto Y, et al. (2010). Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes 59: 2612-2624.
18. Lian H, Ma Y, Feng J, Dong W, Yang Q, Lu D, et al. (2012). Heparin-binding EGF-like growth factor induces heart interstitial fibrosis via an Akt/mTor/p70s6k pathway. PLoS ONE 7: e44946.
19. McRae MY, Adams S, Pereira J, Parsi K, Wargon O, (2013). Venous malformations: clinical course and management of vascular birthmark clinic cases. Australas J Dermatol 54: 22-30.
20. Marler JJ, Mulliken JB, (2001). Vascular anomalies: classification, diagnosis, and natural history. Facial Plast Surg Clin North Am 9: 495-504.
21. Medici D, Potenta S, Kalluri R, (2011). Transforming growth factor-beta2 promotes Snail-mediated endothelial-mesenchymal transition through convergence of Smad-dependent and Smad-independent signalling. Biochem J 437: 515-520.
22. Mouratis MA, Aidinis V, (2011). Modeling pulmonary fibrosis with bleomycin. Curr Opin Pulm Med 17: 355-361.
23. Muir T, Kirsten M, Fourie P, Dippenaar N, Ionescu GO, (2004). Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations. Pediatr Surg Int 19: 766-773.
24. Odeyinde SO, Kangesu L, Badran M, (2013). Sclerotherapy for vascular malformations: complications and a review of techniques to avoid them. J Plast Reconstr Aesthet Surg 66: 215-223.
25. Ohta H, Chiba S, Ebina M, Furuse M, Nukiwa T, (2012). Altered expression of tight junction molecules in alveolar septa in lung injury and fibrosis. Am J Physiol Lung Cell Mol Physiol 302: L193-L205.
26. Palma-Nicolás JP, Lõpez-Colomé AM, (2013). Thrombin induces slug-mediated E-cadherin transcriptional repression and the parallel up-regulation of N-cadherin by a transcription-independent mechanism in RPE cells. J Cell Physiol 228: 581-589.
27. Piera-Velazquez S, Li Z, Jimenez SA, (2011). Role of endothelial- mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol 179: 1074-1080.
28. Ruvinsky I, Meyuhas O, (2006). Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 31: 342-348.
29. Sabbah M, Emami S, Redeuilh G, Julien S, Prevost G, Zimber A, et al. (2008). Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat 11: 123-151.
30. Sun ZJ, Cai Y, Chen G, Wang R, Jia J, Chen XM, et al. (2010). LMO2 promotes angiogenesis probably by up-regulation of bFGF in endothelial cells: an implication of its pathophysiological role in infantile haemangioma. Histopathology 57: 622-632.
31. Thiery JP, Acloque H, Huang RY, Nieto MA, (2009). Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
32. Tulek B, Kiyan E, Toy H, Kiyici A, Narin C, Suerdem M, (2011). Anti-inflammatory and anti-fibrotic effects of sirolimus on bleomycin-induced pulmonary fibrosis in rats. Clin Invest Med 34: E341.
33. Wouters V, Limaye N, Uebelhoer M, Irrthum A, Boon LM, Mulliken JB, et al. (2010). Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects. Eur J Hum Genet 18: 414-420.
34. Yamamoto T, Katayama I, (2011). Vascular changes in bleomycin-iduced scleroderma. Int J Rheumatol 2011. doi: 10.1155/2011/270938.
35. Yoshimatsu Y, Watabe T, (2011). Roles of TGF-beta signals in endothelial-mesenchymal transition during cardiac fibrosis. Int J Inflamm 2011. doi: 10.4061/2011/724080.
36. Yoshizaki A, Yanaba K, Iwata Y, Komura K, Ogawa F, Takenaka M, et al. (2010). Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum 62: 2476-2487.
37. Yu SY, Liu L, Li PU, Li J, (2013). Rapamycin inhibits the mTOR/p70S6K pathway and attenuates cardiac fibrosis in adriamycin-induced dilated cardiomyopathy. Thorac Cardiovasc Surg 61: 223-228.
38. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, et al. (2007). Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13: 952-961.
39. Zou HX, Jia J, Zhang WF, Sun ZJ, Zhao YF, (2013). Propranolol inhibits endothelial progenitor cell homing: a possible treatment mechanism of infantile hemangioma. Cardiovasc Pathol 22: 203-210.